Table 1.
Baseline characteristics by ECG-LVH and prolonged QTa (n = 24 948)
| Characteristic | No ECG-LVH (n = 22 526) |
ECG-LVH (n = 2422) |
P-valuea | ||
|---|---|---|---|---|---|
| No prolonged QTa (n = 21 867) | Prolonged QTa (n = 659) | No prolonged QTa (n = 2261) | Prolonged QTa (n = 161) | ||
| Age, mean (SD), years | 64 (9.3) | 69 (9.6) | 66 (9.1) | 72 (9.6) | <0.0001 |
| Male (%) | 9754 (45) | 420 (64) | 941 (42) | 94 (58) | <0.0001 |
| Black (%) | 8320 (38) | 213 (32) | 1372 (61) | 83 (52) | <0.0001 |
| Current smoker (%) | 3189 (15) | 80 (12) | 201 (8.9) | 17 (11) | <0.0001 |
| Diabetes (%) | 4335 (20) | 169 (26) | 629 (28) | 59 (37) | <0.0001 |
| Systolic blood pressure, mean (SD) (mmHg) | 126 (16) | 130 (17) | 134 (18) | 135 (19) | <0.0001 |
| Body mass index, mean (SD) (kg/m2) | 29.1 (6.1) | 28.9 (5.9) | 31.2 (6.1) | 30.4 (6.4) | <0.0001 |
| Aspirin (%) | 9199 (42) | 365 (55) | 983 (43) | 96 (60) | <0.0001 |
| Warfarin (%) | 595 (2.7) | 76 (12) | 70 (3.1) | 12 (7.5) | <0.0001 |
| Statin (%) | 6618 (30) | 258 (39) | 739 (33) | 71 (44) | <0.0001 |
| Antihypertensive medications (%) | 10 837 (50) | 441 (67) | 1532 (68) | 128 (80) | <0.0001 |
| Atrial fibrillation (%) | 1658 (7.6) | 141 (21) | 187 (8.3) | 22 (14) | <0.0001 |
| Coronary heart disease (%) | 3363 (15) | 257 (39) | 482 (21) | 76 (47) | <0.0001 |
| QT prolonging medications (%) | 5330 (24) | 212 (32) | 510 (23) | 50 (31) | <0.0001 |
ECG-LVH, electrocardiographic left ventricular hypertrophy; QTa, heart rate-adjusted QT interval; SD, standard deviation.
aStatistical significance for categorical variables was tested using the χ2 method and for continuous variables the Kruskal–Wallis procedure was used.